DiaMedica Inc
News
Insiders See US$9.05m Investment In DiaMedica Therapeutics Jump Last Week
Simply Wall St Insiders who bought DiaMedica Therapeutics Inc. ( NASDAQ:DMAC ) stock in the last 12 months were richly rewarded last...\n more…
DiaMedica Therapeutics Upcoming Conference Participation
Business Wire DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke and...\n more…
Is Atossa Genetics (ATOS) Outperforming Other Medical Stocks This Year?
Zacks Investment Research The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Atossa Genetics Inc. (ATOS) one of those stocks right now...\n more…
DiaMedica Therapeutics (NASDAQ:DMAC) Earns Outperform Rating from Oppenheimer
Ticker Report Oppenheimer reiterated their outperform rating on shares of DiaMedica Therapeutics (NASDAQ:DMAC - Free Report) in a research report sent to investors on Friday, Benzinga reports. Oppenheimer...\n more…
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Short Interest Down 17.0% in July
Ticker Report DiaMedica Therapeutics Inc. (NASDAQ:DMAC - Get Free Report) saw a large decrease in short interest in the month of July. As of July 31st, there was short interest totalling 144,200 shares, a decrease...\n more…
DMAC Stock Earnings: DiaMedica Therapeutics Beats EPS for Q2 2024
InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nDMAC stock results show that DiaMedica Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.\nThe post...\n more…